This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Markets Mixed Ahead of Key Inflation Data
by Mark Vickery
Tomorrow morning, the Producer Price Index (PPI) will demonstrate levels of wholesale inflation.
Bio-Rad (BIO) Faces Low BioPharma Demand, Competitive Pressure
by Zacks Equity Research
Bio-Rad (BIO) is experiencing weaker sales in Asia as China is currently entangled in a challenging research funding environment, and Japan, too, is facing constrained funding issues.
Why UnitedHealth Group (UNH) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Should Invesco S&P 500 Revenue ETF (RWL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for RWL
Pediatrix (MD) Q2 Earnings Top on Stable Volumes, Shares Up 7.4%
by Zacks Equity Research
Pediatrix's (MD) second-quarter earnings benefit from stable patient volumes. Rising expenses act as a partial offset.
Is Trending Stock UnitedHealth Group Incorporated (UNH) a Buy Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to UnitedHealth (UNH). This makes it worthwhile to examine what the stock has in store.
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
by Zacks Equity Research
Sector ETF report for IHF
Select Medical's (SEM) Stock Down 16.9% Despite Q2 Earnings Beat
by Zacks Equity Research
Select Medical (SEM) expects its adjusted EBITDA between $845 million and $885 million for 2024, the mid-point of which implies a 7.1% rise from the 2023 reported figure of $807.4 million.
Earnings Growth & Price Strength Make UnitedHealth Group (UNH) a Stock to Watch
by Zacks Equity Research
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
Beat the Market Like Zacks: Motorola, UnitedHealth, Virtu in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Should SPDR Dow Jones Industrial Average ETF (DIA) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DIA
Teladoc Health (TDOC) Shares Down 8.9% Despite Q2 Earnings Beat
by Zacks Equity Research
Teladoc Health (TDOC) expects revenue growth in the Integrated Care segment to be within low to mid-single-digit growth in 2024, on a year-over-year basis.
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RSPH
Cigna (CI) Q2 Earnings Top on Specialty Business Strength
by Zacks Equity Research
Cigna's (CI) Q2 results reflect new client wins in the Evernorth Health Services unit, partly offset by elevated pharmacy costs. It continues to expect adjusted EPS of at least $28.40 for 2024.
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
Ensign Group (ENSG) Q2 Earnings Beat on Occupancy, Stock Up 7.2%
by Zacks Equity Research
Ensign Group's (ENSG) second-quarter results benefit from improved occupancy and skilled services revenue. Higher expenses partially offset the results.
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
UnitedHealth (UNH) Q2 Success: A Turnaround Worth Investing in?
by Kaibalya Pravo Dey
UnitedHealth (UNH) is navigating its challenges effectively, maintaining a positive outlook for the future while demonstrating a strong commitment to its clients and shareholders.
Centene (CNC) Q2 Earnings Miss on Declining Medicaid Membership
by Zacks Equity Research
Centene's (CNC) second-quarter earnings suffer from rising operating expenses and a decline in Medicaid membership levels. Improved Marketplace membership growth partially offset the negatives.
Zacks Industry Outlook Highlights UnitedHealth, The Cigna and Centene
by Zacks Equity Research
UnitedHealth, The Cigna and Centene are part of the Zacks Industry Outlook article.
Here's Why UnitedHealth Group (UNH) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Community Health (CYH) Q2 Earnings Miss on Lower Patient Days
by Zacks Equity Research
Community Health's (CYH) second-quarter earnings suffer a setback from lower admissions and patient days. Improved occupancy levels partially offset the negatives.
Universal Health (UHS) Q2 Earnings Beat on Acute Care Strength
by Zacks Equity Research
Universal Health's (UHS) second-quarter results benefit from the rising number of patients in the Acute Care Unit. Declining admissions in the Behavioral Health segment partially offset the positives.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
UnitedHealth Group Incorporated (UNH) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to UnitedHealth (UNH). This makes it worthwhile to examine what the stock has in store.